|
Name |
Episterol
|
Molecular Formula | C28H46O | |
IUPAC Name* |
(3S,5S,9R,10S,13R,14R,17R)-10,13-dimethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
|
|
SMILES |
C[C@H](CCC(=C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2=CC[C@@H]4[C@@]3(CC[C@@H](C4)O)C)C
|
|
InChI |
InChI=1S/C28H46O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h10,18,20-22,24-26,29H,3,7-9,11-17H2,1-2,4-6H3/t20-,21+,22+,24-,25+,26+,27+,28-/m1/s1
|
|
InChIKey |
BTCAEOLDEYPGGE-JVAZTMFWSA-N
|
|
Synonyms |
Episterol; 474-68-0; 24-methylene-cholest-7-en-3beta-ol; Ergosta-7,24(28)-dien-3-ol; LMST01030115; CHEBI:23929; DTXSID40963827; 5a-ergosta-7,24(28)-dien-3b-ol; (3S,5S,9R,10S,13R,14R,17R)-10,13-dimethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 5alpha-ergosta-7,24(28)-dien-3beta-ol; (3beta,5alpha)-ergosta-7,24(28)-dien-3-ol; Ergosta-7,24(28)-dien-3-ol, (3beta,5alpha)-; Q61014523
|
|
CAS | 474-68-0 | |
PubChem CID | 5283662 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 398.7 | ALogp: | 8.4 |
HBD: | 1 | HBA: | 1 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 20.2 | Aromatic Rings: | 4 |
Heavy Atoms: | 29 | QED Weighted: | 0.467 |
Caco-2 Permeability: | -4.641 | MDCK Permeability: | 0.00004510 |
Pgp-inhibitor: | 0.234 | Pgp-substrate: | 0.015 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.989 |
30% Bioavailability (F30%): | 0.935 |
Blood-Brain-Barrier Penetration (BBB): | 0.025 | Plasma Protein Binding (PPB): | 96.65% |
Volume Distribution (VD): | 1.1 | Fu: | 1.80% |
CYP1A2-inhibitor: | 0.149 | CYP1A2-substrate: | 0.282 |
CYP2C19-inhibitor: | 0.146 | CYP2C19-substrate: | 0.917 |
CYP2C9-inhibitor: | 0.292 | CYP2C9-substrate: | 0.156 |
CYP2D6-inhibitor: | 0.055 | CYP2D6-substrate: | 0.884 |
CYP3A4-inhibitor: | 0.85 | CYP3A4-substrate: | 0.367 |
Clearance (CL): | 7.299 | Half-life (T1/2): | 0.047 |
hERG Blockers: | 0.038 | Human Hepatotoxicity (H-HT): | 0.107 |
Drug-inuced Liver Injury (DILI): | 0.051 | AMES Toxicity: | 0.003 |
Rat Oral Acute Toxicity: | 0.036 | Maximum Recommended Daily Dose: | 0.641 |
Skin Sensitization: | 0.521 | Carcinogencity: | 0.026 |
Eye Corrosion: | 0.819 | Eye Irritation: | 0.69 |
Respiratory Toxicity: | 0.41 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005968 | 1.000 | D0G3SH | 0.481 | ||||
ENC004735 | 0.667 | D03ZTE | 0.481 | ||||
ENC002718 | 0.588 | D0Y7LD | 0.455 | ||||
ENC003557 | 0.560 | D0M4WA | 0.434 | ||||
ENC000609 | 0.481 | D0OR2L | 0.395 | ||||
ENC005630 | 0.477 | D0K5WS | 0.374 | ||||
ENC000125 | 0.477 | D00VZZ | 0.371 | ||||
ENC000961 | 0.468 | D08SVH | 0.361 | ||||
ENC001107 | 0.455 | D0B4RU | 0.346 | ||||
ENC001008 | 0.455 | D02ZGI | 0.339 |